SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... Nature medicine 27 (4), 622-625, 2021 | 1272 | 2021 |
T cell responses to SARS-CoV-2 spike cross-recognize Omicron R Keeton, MB Tincho, A Ngomti, R Baguma, N Benede, A Suzuki, K Khan, ... Nature 603 (7901), 488-492, 2022 | 496 | 2022 |
Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy E Cassol, S Malfeld, P Mahasha, S Van der Merwe, S Cassol, ... The Journal of infectious diseases 202 (5), 723-733, 2010 | 269 | 2010 |
SARS-CoV-2 501Y CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv …, 2021 | 201 | 2021 |
HIV as a cause of immune activation and immunosenescence T Sokoya, HC Steel, M Nieuwoudt, TM Rossouw Mediators of inflammation 2017, 2017 | 173 | 2017 |
Prevalence of Scientific Misconduct Among a Group of Researchers in N igeria P Okonta, T Rossouw Developing world bioethics 13 (3), 149-157, 2013 | 124 | 2013 |
Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B. 1.351) T Moyo-Gwete, M Madzivhandila, Z Makhado, F Ayres, D Mhlanga, ... New England Journal of Medicine 384 (22), 2161-2163, 2021 | 114 | 2021 |
Disruption in the regulation of immune responses in the placental subtype of preeclampsia J Geldenhuys, TM Rossouw, HA Lombaard, MM Ehlers, MM Kock Frontiers in Immunology 9, 361648, 2018 | 100 | 2018 |
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals SI Richardson, VS Madzorera, H Spencer, NP Manamela, ... Cell Host & Microbe 30 (6), 880-886. e4, 2022 | 93 | 2022 |
“It’s my blood”: ethical complexities in the use, storage and export of biological samples: perspectives from South African research participants K Moodley, N Sibanda, K February, T Rossouw BMC medical ethics 15, 1-7, 2014 | 93 | 2014 |
Guidelines for antiretroviral therapy in adults G Meintjes, G Maartens Southern African Journal of HIV Medicine 13 (3), 114-133, 2012 | 79 | 2012 |
The role of transforming growth factor beta-1 in the progression of HIV/AIDS and development of non-AIDS-defining fibrotic disorders AJ Theron, R Anderson, TM Rossouw, HC Steel Frontiers in immunology 8, 311158, 2017 | 76 | 2017 |
Misconduct in research: a descriptive survey of attitudes, perceptions and associated factors in a developing country PI Okonta, T Rossouw BMC medical ethics 15, 1-8, 2014 | 75 | 2014 |
HIV and haematopoiesis C Durandt, JC Potgieter, R Khoosal, JG Nel, CL Herd, J Mellet, ... South African Medical Journal 109 (8 Supplement 1), S41-S46, 2019 | 67 | 2019 |
HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS SH Mayaphi, TM Rossouw, DJ Martin, DP Masemola, SAS Olorunju, ... South African Medical Journal 102 (3), 157-162, 2012 | 61 | 2012 |
SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron R Keeton, MB Tincho, A Ngomti, R Baguma, N Benede, A Suzuki, K Khan, ... MedRxiv, 2021.12. 26.21268380, 2021 | 60 | 2021 |
Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection G Malherbe, HC Steel, S Cassol, T De Oliveira, CJ Seebregts, ... Mediators of inflammation 2014, 2014 | 54 | 2014 |
SARS-CoV-2 501Y. V2 (B. 1.351) elicits cross-reactive neutralizing antibodies T Moyo-Gwete, M Madzivhandila, Z Makhado, F Ayres, D Mhlanga, ... bioRxiv, 2021 | 52 | 2021 |
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity SI Richardson, NP Manamela, BM Motsoeneng, H Kaldine, F Ayres, ... Cell Reports Medicine 3 (2), 2022 | 51 | 2022 |
Interactions of HIV and antiretroviral therapy with neutrophils and platelets M Madzime, TM Rossouw, AJ Theron, R Anderson, HC Steel Frontiers in immunology 12, 634386, 2021 | 48 | 2021 |